Karolinska Development Yönetim

Yönetim kriter kontrolleri 3/4

Karolinska Development CEO'su Viktor Drvota, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı SEK 4.73M olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.9% maaş ve 37.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.078% ine doğrudan sahiptir ve bu hisseler SEK 222.16K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 2.8 yıldır.

Anahtar bilgiler

Viktor Drvota

İcra Kurulu Başkanı

SEK 4.7m

Toplam tazminat

CEO maaş yüzdesi	62.9%
CEO görev süresi	7.4yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	4.5yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Viktor Drvota'un ücretlendirmesi Karolinska Development'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 29m
Jun 30 2024	n/a	n/a	-SEK 6m
Mar 31 2024	n/a	n/a	SEK 34m
Dec 31 2023	SEK 5m	SEK 3m	SEK 5m
Sep 30 2023	n/a	n/a	SEK 17m
Jun 30 2023	n/a	n/a	-SEK 41m
Mar 31 2023	n/a	n/a	-SEK 87m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 88m
Sep 30 2022	n/a	n/a	-SEK 118m
Jun 30 2022	n/a	n/a	-SEK 72m
Mar 31 2022	n/a	n/a	SEK 166m
Dec 31 2021	SEK 5m	SEK 3m	SEK 171m
Sep 30 2021	n/a	n/a	SEK 276m
Jun 30 2021	n/a	n/a	SEK 108m
Mar 31 2021	n/a	n/a	-SEK 106m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 207m
Sep 30 2020	n/a	n/a	SEK 35m
Jun 30 2020	n/a	n/a	SEK 190m
Mar 31 2020	n/a	n/a	SEK 195m
Dec 31 2019	SEK 6m	SEK 3m	SEK 303m
Sep 30 2019	n/a	n/a	-SEK 11m
Jun 30 2019	n/a	n/a	SEK 8m
Mar 31 2019	n/a	n/a	SEK 32m
Dec 31 2018	SEK 5m	SEK 3m	SEK 31m
Sep 30 2018	n/a	n/a	SEK 48m
Jun 30 2018	n/a	n/a	SEK 238m
Mar 31 2018	n/a	n/a	SEK 185m
Dec 31 2017	SEK 5m	SEK 1m	SEK 180m

Tazminat ve Piyasa: Viktor 'ın toplam tazminatı ($USD 430.34K ) UK pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 353.74K ).

Tazminat ve Kazançlar: Viktor 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Viktor Drvota (59 yo)

7.4yrs

Görev süresi

SEK 4,733,000

Tazminat

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Viktor Drvota	Chief Executive Officer	7.4yrs	SEK 4.73m	0.078% SEK 222.2k
Hans Toll	Chief Financial Officer	2.1yrs	Veri yok	0.013% SEK 37.0k
Per Aniansson	Investment Director	3.7yrs	Veri yok	0.059% SEK 169.3k
Eva Montgomerie	Head of Accounting	11.1yrs	Veri yok	0.012% SEK 35.0k
John Öhd	Chief Scientific Officer & Venture Partner	4.4yrs	Veri yok	Veri yok
Johan Dighed	Chief Legal Officer & Deputy CEO	4.5yrs	Veri yok	0.15% SEK 423.4k
Yan Cheng	President of Asia	7.3yrs	Veri yok	0.0093% SEK 26.5k
Tse Ping	Senior Strategic Advisor	no data	Veri yok	Veri yok
Linda Spahiu	Investment Manager	no data	Veri yok	0.0037% SEK 10.6k
Mikaela Sörman	Investment Manager	no data	Veri yok	0.0037% SEK 10.6k

4.5yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: 0P3C 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans Wigzell	Chairman	less than a year	SEK 500.00k	Veri yok
Anna Lefevre Skjoldebrand	Independent Director	3.8yrs	SEK 200.00k	Veri yok
Ben Toogood	Director	3.8yrs	SEK 178.00k	0.024% SEK 67.7k
Will Zeng	Director	no data	Veri yok	Veri yok
Philip Duong	Director	2.8yrs	SEK 200.00k	Veri yok

2.8yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0P3C 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Karolinska Development Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought kr81k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Recent updates

Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines

Less than half of directors are independent

An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

New major risk - Revenue and earnings growth

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

First quarter 2023 earnings released

Less than half of directors are independent

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Second quarter 2022 earnings released

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Investor sentiment deteriorated over the past week

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Less than half of directors are independent

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş